biOasis Technologies Ord Shs V.BTI.H

RE:RE:RE:RE:RE:RE:RE:RE:Denali Hunter Data

[prophetoffactz]

"About you touting Denali's revenue, Denali's loss per share detailed in the last annual report amount to USD $2.39 per share.  That LOSS per share is almost 20 times what a share of Bioasis costs today. Per share, the loss is almost 20 times what a Bioasis is worth. Ponder that!"

You touted Denali's market cap relative to BTI's. I simply mentioned Chiesi has 2.42 billion EURO in annual revenue. That's BTI's strategic partner and Chiesi also has the strategic Fabry asset, etc. 

"No matter the FDA approval status of PRX102 for Fabry disease, Chiesi and Protalix haven't yet submitted an application for IND approval for xB3-PRX102, meaning that clinical trial completion and FDA approval, even with accelerated approvals, aren't likely for years. There will be no clinical trials without IND approval."

BTI's market cap is only C$12.3 million. Not much of anything is priced in. BTI expects to initiate clinical trials for Hunter late next year as Denali validates a path for brain delivery. A broader deal with Chiesi in the next year could be very significant.

Chiesi's expected timeline for Fabry as BTI expects to initate Hunter trials in late 2023 and advances Gaucher's to the human trial goaline:

BLA submission to the FDA – 2H:22

PRX-115 to start Phase I – 1Q:23

EMA approval for PRX-102 – 1H:23

FDA approval for PRX-102 – 1H:23

BTI has a portflio of LSDs advancing with Chiesi as Denali validates a path for LSD brain delivery. Given BTI's current market cap nothing much is priced in. BTI is also targeting neurodegeneration for Fabry, etc. Neurodegeneration is also important for LSDs beyond just Fabry.

Gene therapies can be very expensive and still have risk.